1. Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study

   • Danila Coradini
   • Cinzia Pellizzaro
   • Maria Grazia Daidone

   OriginalPaper Pages: 207 - 217

2. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice

   • Heleen A. Bardelmeijer
   • Mariët Ouwehand
   • Olaf van Tellingen

   OriginalPaper Pages: 219 - 229

3. Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent

   • Gary P. Wilkinson
   • James P. Taylor
   • Paul M. Loadman

   OriginalPaper Pages: 231 - 240

4. In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug

   • Esther F. A. Brandon
   • Rolf W. Sparidans
   • Jan H. M. Schellens

   OriginalPaper Pages: 241 - 251

5. A novel mammalian cell-based approach for the discovery of anticancer drugs with reduced cytotoxicity on non-dividing cells

   • Valeria Gonzalez-Nicolini
   • Cornelia Fux
   • Martin Fussenegger

   OriginalPaper Pages: 253 - 262

6. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

   • K. Gelmon
   • H. Hirte
   • E. Eisenhauer

   OriginalPaper Pages: 263 - 275

7. Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma

   • Thomas E. Hutson
   • Ram Ganapathi
   • Ronald M. Bukowski

   OriginalPaper Pages: 277 - 284

8. Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients

   • Alex Sparreboom
   • Sharon Marsh
   • Howard L. McLeod

   OriginalPaper Pages: 285 - 289

9. Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

   • Valerie Israel
   • Scott T. Tagawa
   • Derek Raghavan

   OriginalPaper Pages: 291 - 297

10. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer

    • Eardie A. Curry III
    • Daryl J. Murry
    • Christopher J. Sweeney

    OriginalPaper Pages: 299 - 305

11. Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer

    • Paulo M. Hoff
    • Everardo D. Saad
    • James L. Abbruzzese

    OriginalPaper Pages: 307 - 313

12. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

    • Susan Burdette-Radoux
    • Richard G. Tozer
    • Elizabeth A. Eisenhauer

    OriginalPaper Pages: 315 - 322

13. 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium

    • Hedy L. Kindler
    • Anjali Avadhani
    • Everett E. Vokes

    OriginalPaper Pages: 323 - 327

14. Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

    • M.J.A. de Jonge
    • J.P. Droz
    • P. Fumoleau

    OriginalPaper Pages: 329 - 333

15. A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study

    • Robert P. Whitehead
    • Jacqueline K. Benedetti
    • John S. Macdonald

    OriginalPaper Pages: 335 - 341

16. Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group

    • Russell J. Schilder
    • John A. Blessing
    • Peter G. Rose

    OriginalPaper Pages: 343 - 349